0714/25SCR019-18/R10RGB
Media Highlights
From the 2025 ASCO® Annual Meeting
7
Media Outlet Article / Coverage
OncLive Adjuvant Chemotherapy Improves DFS in Molecularly
Higher-Risk NSCLC
OncLive Dr Spigel on Adjuvant Chemotherapy in Stage IA/IIA,
Molecularly Higher-Risk NSCLC
OncLive Dr Spigel on a 14-Gene Assay for Clarifying the Benefit of
Adjuvant Chemo in NSCLC
Oncology News ASCO 2025: Molecular Assay May Help Identify People with
NSCLC Who Could Benefit from Adjuvant Chemotherapy
Oncology Nursing News Chemo With Molecular Guidance Improves Survival in Early
NSCLC
Oncology Learning Network Molecular Assay Accurately Identifies Patients With Non-
Small Cell Lung Cancer Who Could Benefit From Adjuvant
Chemotherapy
Oncology Learning Network Molecular Assay May Predict Patients With Non-Small Cell
Lung Cancer to Benefit From Adjuvant Therapy
Pharmacy Times Informing Treatment Decisions Using a 14-Gene Assay in
Early Non-Small Cell Lung Cancer
Physician's Weekly American Society of Clinical Oncology, May 31-June 3
Targeted Oncology Molecularly Guided Chemotherapy Boosts Survival in Early
NSCLC
Targeted Oncology Dr Spigel Covers the AIM-HIGH Trial in Early NSCLC
David Spigel, MD
SCRI
